Q2 2024 Apellis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Apellis Pharmaceuticals Inc (APLS) reported strong revenue growth with total revenue for Q2 2024 reaching approximately $200 million, including $155 million from Sipho Greek and $24.5 million from FLUS net product revenue.
- The company has a clear path to positive cash flow, bolstered by a strategic non-dilutive refinancing collaboration with Sixth Street, which improved liquidity and financial flexibility.
- Sipho Greek continues to show strong market performance, maintaining a 75% market share in the treated GA market and achieving double-digit percentage growth every quarter since launch.
- The company is advancing its pipeline with multiple earlier-stage development programs and expects to share progress at an upcoming investor day.
- Apellis Pharmaceuticals Inc (APLS) has secured broad coverage for Sipho Greek with two large national pharmacy benefit managers making it the preferred treatment on their commercial formularies.
- There are concerns about the competitive landscape for Cytori, with competitors experiencing tailwinds from new J-codes and other factors.
- The European GA opportunity faces uncertainties, with the CHMP reexamination process still ongoing and no guarantee of a positive outcome.
- The company reported a net loss of $38 million for the second quarter, despite strong revenue growth.
- There is a competitive market for PNH treatments, with the availability of an oral treatment impacting sales and leading to flat sales expectations for the next six to twelve months.
- The company faces challenges in expanding the GA market, with only 13% of diagnosed GA patients currently being treated and a need to increase awareness and education among eye care providers.
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Apellis Pharmaceuticals Second Quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session to ask a question. During the session, you will need to press star one on your telephone.
You will then hear an automated message. Advising your hand is raised. To withdraw your question, please press star one. Again. Please be advised that today's conference is being recorded. I would now like to introduce, I would now like to hand the conference over to Meredith Kaya, Senior Vice President, Investor Relations and Strategic Finance. Please go ahead.
Good morning, and thank you for joining us to discuss Apellis Second Quarter 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois, Chief Operating Officer, Adam Townsend, Chief Medical Officer,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
